Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 6, 2007, Pages 423-425

  Veziris, N ^a   Martin, C ^b   Brossier, F ^a   Bonnaud, F ^b   Denis, F ^b   Aubry, A ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENETICS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FOLLOW UP; GENE MUTATION; HUMAN; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPUTUM ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FATAL OUTCOME; FLUOROQUINOLONES; HUMANS; LUNG; MALE; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 34249888180     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0298-0     Document Type: Article

References (10)

1. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ et al (2006) Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194:479-485
2. Centers for Disease Control and Prevention (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. Morb Mortal Wkly Rep 55:301-305
3. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M et al (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 169:1103-1109
4. World Health Organization (2006) Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 81:430-432
5. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V (1999) Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 43:1761-1763
6. Guillemin I, Jarlier V, Cambau E (1998) Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 42:2084-2088
7. Maus CE, Plikaytis BB, Shinnick TM (2005) Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:3192-3197
8. Jarlier V, Philippon A, Nicolas MH, Bismuth R, Paul G, Fusciardi J (1984) [Enterobacter cloacae. In vivo emergence of a variant resistant to new beta-lactams during treatment with lamoxactam-gentamicin]. Pathol Biol (Paris) 32:399-403
9. Elliott AM, Berning SE, Iseman MD, Peloquin CA (1995) Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis 76:463-467
10. World Health Organization (2006) Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva